Influence of growth hormone on cardiovascular health and disease

Treatments in Endocrinology

Volumn 2, Issue 5, 2003, Pages 347-356

  Colao, Annamaria ^a   Di Somma, Carolina ^a   Vitale, Giovanni ^a   Filippella, Mariagiovanna ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DISEASE ASSOCIATION; GROWTH HORMONE DEFICIENCY; HEALTH; HEART DEVELOPMENT; HEART FAILURE; HEART FUNCTION; HEMODYNAMICS; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANIMALS; CARDIAC OUTPUT, LOW; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; HUMAN GROWTH HORMONE; HUMANS; PEPTIDE HORMONES;

EID: 0042693196     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200302050-00006     Document Type: Review

References (100)

1. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res 1995; 30: 825-34
2. Toyozaki T, Hiroe M, Hasumi M, et al. Insulin like growth factor I receptors in human cardiac myocytes and their relation to myocardial hypertrophy. Jpn Circ J 1993; 57: 1120-7
3. Huchard H. Anatomie pathologique, lesions et trouble cardiovasculaires de l'acromegalie. J Practiciens 1895; 9: 249-50
4. Colao A, Marzullo P, Di Somma C, et al. Growth hormone and the heart. Clin Endocrinol (Oxf) 2001 Feb; 54 (2): 137-54
5. Bates AS, Van't Hoff W, Jones JM, et al. An audit of outcome of treatment in acromegaly. Q J Med 1993; 86: 293-9
6. Bates AS, Vant'Hoff W, Jones PJ, et al. The effect of hypopituitary on life expectancy. J Clin Endocrinol Metab 1996; 81: 1169-72
7. Bengtsson B-A, Bergh CH, Caidahl K, et al. An overview of cardiac function and implication for growth hormone: cardiomyopathy. J Endocrinol Invest 1998; 21: 80-3
8. Bulöw B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997; 46: 75-81
9. Nabarro JDN. Acromegaly. Clin Endocrinol (Oxf) 1987; 26: 481-512
10. Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study: United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83: 2730-4
11. Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41: 95-102
12. Rosén T, Bengtsson B-A. Premature cardiovascular mortality in hypopituitarism: a study of 333 consecutive patients. Lancet 1990; 336: 285-8
13. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994; 15: 555-73
14. Wright AD, Hill DM, Lowy C, et al. Mortality in acromegaly. Q J Med 1970; 39: 1-16
15. Guron G, Friberg P, Wickman A, et al. Cardiac insulin-like growth factor I and growth hormone receptor expression in renal hypertension. Hypertension 1996; 27: 636-42
16. Kluge A, Zimmermann R, Weihrauch D, et al. Coordinate expression of the insulin-like growth factor system after microembolisation in porcine heart. Cardiovasc Res 1997; 33: 324-31
17. Schaper W, Zimmermann R, Kluge A, et al. Patterns of myocardial gene expression after cycles of brief coronary occlusion and reperfusion. Ann N Y Acad Sci 1994; 723: 284-91
18. Dean R, Edmondson SR, Burrell LM, et al. Localization of the insulin-like growth factor system in a rat model of heart failure induced by myocardial infarction. J Histochem Cytochem 1999; 47: 649-60
19. Cittadini A, Ishiguro Y, Strömer H, et al. Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circ Res 1998; 83: 50-9
20. Freestone NS, Ribaric S, Mason WT. The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Mol Cell Biochem 1996; 163: 223-9
21. Xu XP, Best PM. Decreased transient outward K+ current in ventricular myocytes from acromegalic rats. Am J Physiol 1991; 260 (3 Pt 2): H935-42
22. Erfurth EM, Hagmar L. Cardiovascular mortality among pituitary insufficient patients. Clin Endocrinol (Oxf) 1998; 49: 271-2
23. Beshyah SA, Johnston DG. Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol (Oxf) 1999; 50: 1-15
24. Beznak M. The restoration of cardiac hypertrophy and blood pressure in hypophysectomized rats by large doses of lyophilized anterior pituitary and growth hormone. J Physiol 1954; 124: 64-74
25. Hjalmarson A, Isaksson O, Martin FI. Effects of growth hormone and insulin on amino acid transport in perfused rat heart. Am J Physiol 1969; 217: 1795-802
26. Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993; 77: 1671-6
27. Merola B, Cittadini A, Colao A, et al. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 1993; 77: 1658-61
28. Beshyah SA, Shahi M, Foale R, et al. Cardiovascular effects of prolonged growth hormone replacement in adults. J Intern Med 1995; 237: 35-42
29. Dunne FP, Elliott P, Gammage MD, et al. Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism. Clin Endocrinol (Oxf) 1995; 43: 623-9
30. Thuesen L, Jorgensen JOL, Muller JR, et al. Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clin Endocrinol (Oxf) 1994; 41: 615-50
31. Valcavi R, Gaddi O, Zini M, et al. Cardiac performance and mass in adult with hypopituitarism: effects of one year of growth hormone treatment. J Clin Endocrinol Metab 1995; 80: 659-66
32. Nass R, Huber RM, Klauss V, et al. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metab 1995; 80: 552-7
33. Longobardi S, Cuocolo A, Merola B, et al. Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. Clin Endocrinol (Oxf) 1998; 48: 137-43
34. Colao A, Cuocolo A, Di Somma C, et al. Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study. Clin Endocrinol (Oxf) 2000; 52: 447-55
35. Toogood AA, O'Neill PA, Shalet SM. Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 1996; 81: 460-5
36. Toogood AA, Adams JE, O'Neill PA, et al. Body composition in growth hormone deficient adult over the age of 60 years. Clin Endocrinol (Oxf) 1996; 45: 399-405
37. Colao A, Cerbone G, Pivonello R, et al. Growth hormone deficiency in elderly patients with hypothalamo-pituitary tumors. Pituitary 1998; 1: 59-67
38. Colao A, Cuocolo A, Di Somma C, et al. Impaired cardiac performance in elderly patients with growth hormone deficiency. J Clin Endocrinol Metab 1999; 85: 3950-5
39. Delafontaine P, Lou H, Alexander RW. Regulation of insulin-like growth factor 1 messenger RNA levels in vascular smooth muscle cells. Hypertension 1991; 18: 742-7
40. Böger RH, Skamira C, Bode-Böger SM, et al. Nitric oxide mediates the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. J Clin Invest 1996; 98: 2706-13
41. Copeland KC, Sreekuran K. Recombinant human insulin-like growth factor-1 increases forearm blood flow. J Clin Endocrinol Metab 1994; 79: 230-2
42. Tsukahara H, Gordienko DV, Tonshoff B, et al. Direct demonstration of insulin-like growth factor I induced nitric oxide production by endothelial cells. Kidney Int 1994; 45: 598-604
43. Hirshberg R, Brunori G, Koppel J, et al. Effects of insulin like growth factor-I on renal function in normal men. Kidney Int 1993; 43: 387-97
44. Guler HP, Eckardt KU, Kapf J, et al. Insulin like growth factor-I increases glomerular filtration rate and renal plasma flow in man. Acta Endocrinol 1989; 121: 101-6
45. Evans LM, Davies JS, Anderson RA, et al. The effects of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol 2000; 142: 254-62
46. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454-6
47. Lehmann ED, Hopkins KD, Weissberger AJ, et al. Aortic distensibility in growth hormone deficient adults [letter]. Lancet 1993; 341: 309
48. Evans LM, Davies JS, Goodfellow J, et al. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin Endocrinol (Oxf) 1999; 50: 457-64
49. Capaldo B, Patti L, Oliviero U, et al. Increased arterial intima-media thickness in childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 1997; 82: 1378-81
50. Borson-Chazot F, Scrusclat A, Kalfallah Y, et al. Decrease in carotid intima-media thickness after I year growth hormone (GH) treatment in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84: 1329-33
51. Pfeifer M, Vcrhovec R, Žižek B, et al. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 1999; 84: 453-7
52. Smith JC, Lang D, McEneny J, et al. Effects of GH on lipid peroxidation and neutrophil superoxide anion-generating capacity in hypopituitary adults with GH deficiency. Clin Endocrinol (Oxf) 2002; 56: 449-55
53. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone adminstration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: a randomized, controlled clinical trial. Ann Intern Med 2000; 133: 111-22
54. Sesmilo G, Miller KK, Hayden D, et al. Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab 2001; 86: 5774-81
55. Sverrisdottir YB, Elam M, Herlitz H, et al. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. J Clin Endocrinol Metab 1998; 83: 1881-5
56. Carrol PV, Christ ER. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998; 83: 382-95
57. Vance ML, Mauras N. Growth hormone therapy in adults and children. N Engl J Med 1999; 341: 1206-16
58. Caidahl K, Edén S, Bengtsson B-A. Cardiovascular and renal effects of growth hormone. Clin Endocrinol (Oxf) 1994; 40: 393-400
59. Johansson G, Bengtsson B-A, Andersson B, et al. Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults: preliminary data in a small group of patients. Clin Endocrinol (Oxf) 1996; 45: 305-14
60. Ter Maaten J, De Boer H, Kamp O, et al. Long-term effects of growth hormone (GH) replacement in men with childhood-onsct GH deficiency. J Clin Endocrinol Metab 1999; 84: 2373-80
61. Gibney J, Wallace JD, Spinks T, et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999; 84: 2596-602
62. Cittadini A, Cuocolo A, Merola B, et al. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am J Physiol 1994; 267 (2 Pt 1): E219-25
63. Cuocolo A, Nicolai E, Colao A, et al. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: assessment with radionuclide angiography. Eur J Nucl Med 1996; 23: 390-4
64. Colao A, Di Somma C, Cuocolo A, et al. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab 2001; 86: 1874-81
65. Johannsson G, Albertsson-Wikland K, Bengtsson BA. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. J Clin Endocrinol Metab 1999; 84: 4516-24
66. Lanes R, Gunczler P, Lopez E, et al. Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents. J Clin Endocrinol Metab 2001; 86: 1061-5
67. Colao A, Di Somma C, Salerno M, et al. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab 2002 Aug; 87 (8): 3650-5
68. Colao A. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J Clin Endocrinol Metab 2002 Mar; 87 (3): 1088-93
69. Bots ML, Hohman A, Grobee DE. Increased common carotid intima-media thickness: adaptative response of a reflection of atherosclerosis? Findings form the Rotterdam Study. Stroke 1997; 28: 2442-7
70. Capaldo B, Guardasole V, Pardo F, et al. Abnormal vascular reactivity in growth hormone deficiency. Circulation 2001; 103: 520-4
71. Duerr RL, Huang S, Miraliakbar HR, et al. Insulin-like growth factor-I enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995; 95: 619-27
72. Duerr RL, Dan McKirnan M, Gim RD, et al. Cardiovascular effects of insulin-like growth factor 1 and growth hormone in chronic left ventricular failure in the rat. Circulation 1996; 93: 2188-96
73. Yang R, Bunting S, Gillett N, et al. Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995; 92: 262-7
74. Jin H, Yang R, Gillett N, et al. Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition. J Cardiovasc Pharmacol 1995; 26: 420-5
75. Cittadini A, Stromer H, Katz SE, et al. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat: a combined in vivo and in vitro evaluation. Circulation 1996; 93: 800-9
76. Strömer H, Cittadini A, Douglas PS, et al. Exogenously administered growth hormone and insulin-like growth factor-1 alter intracellular Ca2+ handling and enhance cardiac performance: in vitro evaluation in the isolated isovolumic buffer-perfused rat heart. Circ Res 1996; 79: 227-35
77. Broglio F, Fubini A, Morello M, et al. Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. Clin Endocrinol (Oxf) 1999; 50: 417-30
78. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of heart failure in patients with dilated cardiomyopathy. N Engl J Med 1996; 334: 809-14
79. Frustaci A, Perrone GA, Gentiloni N, et al. Reversible dilated cardiomyopathy due to growth hormone deficiency. Am J Clin Pathol 1996; 97: 503-11
80. Volterrani M, Desenzani P, Lorusso R, et al. Hemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet 1997; 349: 1067-8
81. Genth-Zotz S, Zotz R, Geil S, et al. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy. Circulation 1999; 99: 18-21
82. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351: 1233-7
83. Perrot A, Ranke MB, Dietz R, et al. Growth hormone treatment in dilated cardiomyopathy. J Card Surg 2001; 16: 127-31
84. Turner H, Wass JAH. Growth hormone in the treatment of dilated cardiomyopathy [letter]. N Engl J Med 1996; 335: 672
85. Frustaci A, Gentiloni N, Russo MA. Growth hormone in the treatment of dilated cardiomyopathy [letter]. N Engl J Med 1996; 335: 672
86. Isgaard J, Bergh C-H, Caidhal K, et al. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 1998; 19: 1704-11
87. Smit JW, Janssen YJ, Lamb HJ, et al. Six month of recombinant human GH therapy in patients ischemic cardiac failure does not influence left ventricular function and mass. J Clin Endocrinol Metab 2001; 86: 4638-43
88. Cuneo RC, Wilmshurst P, Lowy C, et al. Cardiac failure responding to growth hormone. Lancet 1989; i (8642): 838-9
89. O'Driscoll JC, Green DJ, Ireland M, et al. Treatment of end-stage cardiac failure with growth hormone [letter]. Lancet 1997; 349: 1068
90. Spallarossa P, Rossettin P, Minuto F, et al. Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease. Am J Cardiol 1999; 84: 430-3
91. Anker SD, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 2001; 38: 443-52
92. Casanueva FF, Dieguez C. Growth hormone secretagogues: physiological role and clinical utility. Trends Endocrinol Metab 1999; 10: 30-8
93. Howard AD, Fieghner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974-7
94. Rossoni G, De Gennaro Colonna V, Bernareggi M, et al. Protectant activity of hexarelin or growth hormone against post-ischemic ventricular dysfunction in hearts from aged rats. J Cardiovasc Pharmacol 1998; 32: 260-5
95. Tivesten A, Bollano E, Caidahl K, et al. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology 2000; 141: 60-6
96. De Gennaro Colonna VG, Rossini M, Bernareggi M, et al. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone deficient rats: protection by hexarelin. Eur J Pharmacol 1997; 334: 201-7
97. Locatelli V, Rossoni G, Schweiger F, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 1999; 140: 4024-31
98. Broglio F, Benso A, Valletto MR, et al. Growth hormone-independent cardiotropic activities of growth hormone realising peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyophaty. Endocrine 2001; 14: 105-8
99. Nagaya N, Miyatake K, Uematsu M, et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with choronic heart failure. J Clin Endocrinol Metab 2001; 86: 5854-9
100. Nagaya N, Kojima M, Uematsu M, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol 2001; 280 (5): R 1483-7